✨ Onyx Summary Guardant Health announced a strategic partnership with PathGroup to expand access to its FDA-approved Shield™ blood test for colorectal cancer screening across 250+ hospitals, 15,000 physicians, and millions of patients in 25 states. By integrating Shield into PathGroup’s vast network and workflows, the collaboration represents a
Industrial relations between doctors and the state have never been worse
✨ Onyx Summary Adverum Biotechnologies granted inducement equity awards to two new employees, consisting of stock options to purchase 16,860 shares and 8,430 restricted stock units under its 2017 Inducement Plan. The awards, made in accordance with Nasdaq Listing Rule 5635(c)(4), align new hires’ incentives with shareholder
✨ Onyx Summary Lexicon Pharmaceuticals will present preclinical data at NeuPSIG 2025 showing pilavapadin (AAK1 inhibitor) reduced neuropathic pain in models of chemotherapy-induced peripheral neuropathy and multiple sclerosis, with a separate poster on the Phase 2b PROGRESS study design. The update broadens pilavapadin’s potential beyond diabetic peripheral neuropathic pain, aligning
✨ Onyx Summary Perspective Therapeutics has appointed Joel Sendek as Chief Financial Officer, effective immediately. Sendek, a veteran biotech finance executive with over $2.5 billion raised across prior CFO roles and a top-ranked equity research background, succeeds Juan Graham and is expected to strengthen the company’s financial and strategic
✨ Onyx Summary Guardant Health reported that its updated Shield™ colorectal cancer screening algorithm (V2) achieved 84% sensitivity and 90% specificity in a clinical validation study, including 62% sensitivity for detecting stage I disease. These results, alongside Shield’s status as the first FDA-approved blood test for CRC screening, underscore its
✨ Onyx Summary Lexicon Pharmaceuticals will present patient-reported outcomes on the impact of diabetic peripheral neuropathic pain at PAINWeek 2025 (Poster #53, Sept. 4, 4:00–5:30 p.m. PT, Las Vegas) led by Belinda Hardin, PharmD, BCPS, and Suma Gopinathan, Ph.D. The findings are intended to inform late-stage
✨ Onyx Summary ✨ Onyx Summary enGene Holdings announced it has reached target enrollment of 100 patients in the pivotal cohort of its Phase 2 LEGEND trial evaluating detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The company plans to overenroll the cohort and now anticipates submitting a Biologics License Application
✨ Onyx Summary Perspective Therapeutics has appointed Maya Martinez-Davis, President of GSK’s U.S. Commercial business, to its Board of Directors as an independent director. Martinez-Davis brings over two decades of biopharma leadership across GSK, Merck KGaA, and Pfizer, strengthening the company’s strategic and commercial expertise as it advances
✨ Onyx Summary Allucent expanded its executive team, appointing Patrick Phillips as COO, Rachel Page as CCO, and Nate Thompson as CIO to strengthen operations, commercial execution, and technology/AI strategy. The hires aim to scale delivery for small and mid-sized biopharma clients, accelerating program execution and reinforcing Allucent’s position
✨ Onyx Summary Lexicon reported a pooled post-hoc analysis of the SCORED and SOLOIST-WHF trials presented at ESC 2025 showing sotagliflozin reduced total CV death and HF events and lowered total MACE versus placebo consistently across age, including ≥65 and ≥75 years. The dataset (~12,000 participants; median age 69) supports
✨ Onyx Summary Ocugen announced that CEO Dr. Shankar Musunuri will present at the H.C. Wainwright Global Investment Conference in New York (Sept. 8–10, 2025) and participate in a regulatory strategy panel at Biotech on Tap in Munich (Sept. 24–26, 2025). The company will also hold one-on-one investor
✨ Onyx Summary MassBio and SCbio announced the 10 startups selected for this fall’s Drive accelerator, which will run parallel biotech and techbio cohorts to support pre-seed companies tackling challenges in immunology, neuroscience, oncology, AI-driven drug discovery, and more. By equipping founders with mentorship, business tools, and investor exposure, the
✨ Onyx Summary Seer, Inc. appointed Isaac Ro, Partner at Catalio Capital Management, to its Board of Directors, adding extensive financial and sector expertise in life science tools and diagnostics. Ro’s background in leading high-growth companies through IPOs, acquisitions, and strategic scaling strengthens Seer’s governance as it advances the
✨ Onyx Summary Keros Therapeutics announced that CEO Jasbir S. Seehra, Ph.D., will present at the Wells Fargo Healthcare Conference on September 4 and the H.C. Wainwright Global Investment Conference on September 9, 2025. The company will provide corporate and program updates, with presentation replays available for 90 days
✨ Onyx Summary Rocket Pharmaceuticals (NASDAQ: RCKT) will present at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences this September, spotlighting its late-stage genetic therapy pipeline for rare cardiovascular and hematologic disorders. With pivotal programs nearing key milestones, Rocket’s presence underscores its transition toward commercialization—an inflection point closely
